Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings.
In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed.
Foa
R
R
Dipartimento di Scienze Biomediche e Oncologia Umana, University of Torino, Italy.
Meloni
G
G
Guarini
A
A
Vignetti
M
M
Marchis
D
D
Tosti
S
S
Tos
A G
AG
Vischia
F
F
Mandelli
F
F
Gavosto
F
F
D000208:Acute Disease; D000328:Adult; D002648:Child; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000627:therapeutic use*; D007558:Italy; D007951:Leukemia, Myeloid / Q000628:therapy*; D012074:Remission Induction
D007376:Interleukin-2